Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Mast cell leukemia is a malignant form of systemic mastocytosis (SM) characterized, most of the time, by the presence of circulating mast cells.
Biomarker and diagnostic research for mast cell leukemia has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
6 clinical trials registered, 2 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and medical devices. Pipeline includes 2 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT01137825](https://clinicaltrials.gov/study/NCT01137825) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 1:53 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Registry of Older Patients With Cancer |
— |
UNC Lineberger Comprehensive Cancer Center |
RECRUITING |
[NCT01137643](https://clinicaltrials.gov/study/NCT01137643) | Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer | — | UNC Lineberger Comprehensive Cancer Center | RECRUITING |
[NCT04996875](https://clinicaltrials.gov/study/NCT04996875) | (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | PHASE2 | Cogent Biosciences, Inc. | UNKNOWN |
[NCT00935090](https://clinicaltrials.gov/study/NCT00935090) | 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer | — | Barbara Ann Karmanos Cancer Institute | ACTIVE_NOT_RECRUITING |
[NCT03779854](https://clinicaltrials.gov/study/NCT03779854) | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | PHASE2 | Fred Hutchinson Cancer Center | ACTIVE_NOT_RECRUITING |
24 publications have been identified in PubMed for mast cell leukemia. Research spans Case Report / Case Series (42%), Review / Meta-Analysis (21%), and Epidemiology / Natural History (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 10 | 42% |
Research summaries | 5 | 21% |
Disease patterns and progression | 3 | 13% |
Other research | 2 | 8% |
Testing and diagnosis research | 2 | 8% |
Clinical study results | 1 | 4% |
Laboratory research | 1 | 4% |
Faraci DG (2026). [PMID: 41669109](https://pubmed.ncbi.nlm.nih.gov/41669109/). *Front Oncol*. [Case Report / Case Series]
Wang L (2026). [PMID: 42087696](https://pubmed.ncbi.nlm.nih.gov/42087696/). *Cytometry B Clin Cytom*. [Other]
Idamakanti M (2025). [PMID: 40904938](https://pubmed.ncbi.nlm.nih.gov/40904938/). *J Hematol*. [Review / Meta-Analysis]
Liang EC (2025). [PMID: 41424934](https://pubmed.ncbi.nlm.nih.gov/41424934/). *Blood Neoplasia*. [Clinical Trial Publication]
Idamakanti M (2025). [PMID: 39935699](https://pubmed.ncbi.nlm.nih.gov/39935699/). *J Hematol*. [Case Report / Case Series]
Li S (2025). [PMID: 39415365](https://pubmed.ncbi.nlm.nih.gov/39415365/). *Int J Lab Hematol*. [Case Report / Case Series]
Lee N (2025). [PMID: 40724530](https://pubmed.ncbi.nlm.nih.gov/40724530/). *Life (Basel)*. [Case Report / Case Series]
Aperna F (2025). [PMID: 40607735](https://pubmed.ncbi.nlm.nih.gov/40607735/). *Am J Hematol*. [Diagnostic / Biomarker]
Soare D (2025). [PMID: 40893810](https://pubmed.ncbi.nlm.nih.gov/40893810/). *J Med Life*. [Epidemiology / Natural History]
Yip AJW (2025). [PMID: 39838115](https://pubmed.ncbi.nlm.nih.gov/39838115/). *Immunol Res*. [Review / Meta-Analysis]